These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 30665496)
1. In Vivo and In Vitro Effects of Vasopressin V2 Receptor Antagonism on Myocardial Fibrosis in Rats. Zhang L; Joseph L; Joseph J Am J Med Sci; 2019 Feb; 357(2):151-159. PubMed ID: 30665496 [TBL] [Abstract][Full Text] [Related]
2. Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V Ali Y; Dohi K; Okamoto R; Katayama K; Ito M Br J Pharmacol; 2019 May; 176(9):1315-1327. PubMed ID: 30801659 [TBL] [Abstract][Full Text] [Related]
3. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion. Chiba H; Seo Y; Sai S; Namekawa M; Ishizu T; Aonuma K Hypertens Res; 2019 Mar; 42(3):319-328. PubMed ID: 30559403 [TBL] [Abstract][Full Text] [Related]
4. Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist. Kolkhof P; Pook E; Pavkovic M; Kretschmer A; Buchmüller A; Tinel H; Delbeck M; Mondritzki T; Wasnaire P; Dinh W; Truebel H; Hüser J; Schmeck C J Cardiovasc Pharmacol; 2019 Jul; 74(1):44-52. PubMed ID: 31274842 [TBL] [Abstract][Full Text] [Related]
5. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529 [TBL] [Abstract][Full Text] [Related]
6. Vasopressin receptor antagonists in heart failure. Hobbs RE; Tang WH Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127 [TBL] [Abstract][Full Text] [Related]
7. Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure. Ikeda T; Iwanaga Y; Watanabe H; Morooka H; Akahoshi Y; Fujiki H; Miyazaki S J Cardiovasc Pharmacol; 2015 Nov; 66(5):487-96. PubMed ID: 26248278 [TBL] [Abstract][Full Text] [Related]
8. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Rangasetty UC; Gheorghiade M; Uretsky BF; Orlandi C; Barbagelata A Expert Opin Investig Drugs; 2006 May; 15(5):533-40. PubMed ID: 16634691 [TBL] [Abstract][Full Text] [Related]
9. Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models. El-Shabrawy M; Mishriki A; Attia H; Emad Aboulhoda B; Emam M; Wanas H Pharmacol Res Perspect; 2020 Oct; 8(5):e00659. PubMed ID: 32996719 [TBL] [Abstract][Full Text] [Related]
10. Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure. Ishikawa M; Kobayashi N; Sugiyama F; Onoda S; Ishimitsu T Int Heart J; 2013; 54(2):98-106. PubMed ID: 23676370 [TBL] [Abstract][Full Text] [Related]
11. Detrimental Impact of Vasopressin V2 Receptor Antagonism in a SU5416/Hypoxia/Normoxia-Exposed Rat Model of Pulmonary Arterial Hypertension. Goto I; Dohi K; Ogihara Y; Okamoto R; Yamada N; Mitani Y; Ito M Circ J; 2016; 80(4):989-97. PubMed ID: 26924211 [TBL] [Abstract][Full Text] [Related]
12. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment. Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667 [TBL] [Abstract][Full Text] [Related]
13. Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats. Yamazaki T; Nakamura Y; Shiota M; Osada-Oka M; Fujiki H; Hanatani A; Shimada K; Miura K; Yoshiyama M; Iwao H; Izumi Y J Pharmacol Sci; 2013 Sep; 123(1):58-66. PubMed ID: 24005048 [TBL] [Abstract][Full Text] [Related]